Feb 8 (Reuters) - Veracyte Inc
* Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis through agreement with quest diagnostics
* Says quest diagnostics is expected to begin offering test to its customers nationally in Q2 of 2017
* Says financial and other terms of agreement were not disclosed.
* Physician clients of quest diagnostics will be able to order test on behalf of patients, refer patient specimens to co for genomic testing Source text for Eikon: Further company coverage: